Objective      To research the pharmacokinetics and antitumor effect of arginine-glycine-aspartic acid (RGD)-modified paclitaxel and microRNA-34a co-loaded liposome (RGD miLPs-34a/PTX) in A549-bearing nude mice.        Methods      Fluorescence spectrophotometry was used to evaluate in vitro stability of RGD miLPs-34a/PTX in 50% fetal bovine serum (FBS) and in vivo pharmacokinetics. Near infrared imaging was adopted to evaluate the targeting efficiency of the liposome. A549 cells were xenografted into athymic mice to establish lung cancer mouse models

which were used to evaluate the antitumor effect of the liposome.       Results      RGD miLPs-34a/PTX could be stable in 50% FBS for 24 h. The elimination of microRNA-34a was much quicker than that of miLPs-34a/PTX and RGD miLPs-34a/PTX (P0.05). Near infrared imaging demonstrated that the accumulation of RGD miLPs-34a/PTX was much higher than that of miLPs-34a/PTX. The antitumor effect of RGD miLPs-34a/PTX was much better than that of other liposomes (P0.05).        Conclusion      RGD miLPs-34a/PTX shows high targeting efficiency and antitumor effect

and is a promising drug delivery system targeting lung cancer.